# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Q & M Dental Group (Singapore) Limited |
| Establishment Date | January 7, 2008 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | EM2AI has successfully deployed AI-powered automated dental charting using x-rays and intra-oral image analysis across clinics in Singapore and Malaysia. The integration of EM2AI's dental AI solutions into a major dental solutions provider's platform is set to expand its reach to over 1,100 clinics across Singapore, Malaysia, Thailand, Vietnam, and Australia. | The Company has made significant investments in Artificial Intelligence (AI), exemplified by the development of the AI Guided Clinical Decision Support System ('AI-GCDSS') and the cloud-based Integrated Dental Management System ('EM2Clinic'). These innovations enhance patient care by providing ethical, efficient, and effective solutions tailored to individual needs. |
| Product Advantages | Q & M operates the largest network of private dental outlets in Singapore, with 106 clinics, and has expanded its offerings through the acquisition of Veritas Dental, enhancing its ability to cater to high-value treatments. The Q & M Patient App facilitates direct communication of dental health reports to patients, representing a significant advancement in patient engagement. | The Group operates the largest network of private dental outlets in Singapore, with 106 clinics, and offers a comprehensive range of dental services, including the recently launched Q & M Free Dental Clinic, which provides essential dental treatment free of charge to needy patients. |
| Brand Recognition | Q & M is recognized as a leading private dental healthcare group in Asia, with a strong commitment to community service exemplified by the Free Dental Clinic at Chai Chee, which provides essential dental care to underserved populations. The company's ongoing efforts in sustainability and CSR initiatives further solidify its reputation as a responsible corporate citizen. | The establishment of the Q & M Free Dental Clinic at Chai Chee, the first of its kind set up by a private dental group in Singapore, underscores the Company's commitment to community service and enhances its reputation as a responsible corporate citizen. |
| Reputation Ratings | The company adheres to the Global Reporting Initiative (GRI) Sustainability Reporting Standards and has published its sustainability report for the eighth consecutive year, demonstrating its commitment to transparency and stakeholder engagement in ESG matters. | The Company adheres to the Global Reporting Initiative ('GRI') Sustainability Reporting Standards, demonstrating its commitment to managing ESG factors for a sustainable future. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | To provide dental services in a sustainable manner |
| Vision Statement | peace - holistic healthcare equity |
| Core Values | Loyalty, Truthfulness, Respect, Righteousness, Integrity |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 180,674.0 | 182,723.0 | 181,214.0 | Thousands | SGD |
| Cost of Goods Sold | (20,428.0) | (21,319.0) | (25,170.0) | Thousands | SGD |
| Gross Profit | N/A | N/A | N/A | Thousands | SGD |
| Operating Expense | (105,886.0) | (108,853.0) | (103,612.0) | Thousands | SGD |
| Operating Income | N/A | N/A | N/A | Thousands | SGD |
| Net Profit | 13,066.0 | 11,073.0 | N/A | Thousands | SGD |
| Income before income taxes | 14,752.0 | 13,664.0 | 14,277.0 | Thousands | SGD |
| Income tax expense(benefit) | (1,686.0) | (2,591.0) | (2,421.0) | Thousands | SGD |
| Interest Expense | 3,724.0 | 3,985.0 | 2,054.0 | Thousands | SGD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Current Assets | 84,061.0 | 80,592.0 | 81,803.0 | Thousands | SGD |
| Non-Current Assets | 163,712.0 | 177,996.0 | 185,609.0 | Thousands | SGD |
| Total Liabilities | 139,266.0 | 155,677.0 | 165,164.0 | Thousands | SGD |
| Current Liabilities | 31,810.0 | 33,286.0 | 32,674.0 | Thousands | SGD |
| Non-Current Liabilities | 107,456.0 | 122,391.0 | 132,490.0 | Thousands | SGD |
| Shareholders' Equity | 108,507.0 | 102,911.0 | 102,248.0 | Thousands | SGD |
| Retained Earnings | 33,674.0 | 27,841.0 | 24,163.0 | Thousands | SGD |
| Total Equity and Liabilities | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Inventories | 10,587.0 | 11,812.0 | 11,091.0 | Thousands | SGD |
| Prepaid Expenses | 1,443.0 | 1,464.0 | 2,144.0 | Thousands | SGD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 40,098.0 | 33,260.0 | 39,746.0 | Thousands | USD |
| Net Cash Flow from Investing | (6,307.0) | (6,955.0) | (10,995.0) | Thousands | USD |
| Net Cash Flow from Financing | (33,442.0) | (32,010.0) | (30,468.0) | Thousands | USD |
| Net Increase/Decrease in Cash | 349.0 | (5,705.0) | (7,913.0) | Thousands | USD |
| Dividends | (8,804.0) | (7,193.0) | (13,152.0) | Thousands | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 111.31% | 111.67% | 113.89% | Thousands | SGD |
| Operating Margin | N/A | N/A | N/A | Thousands | SGD |
| Net Profit Margin | 7.23% | 6.06% | N/A | Thousands | SGD |
| Current Ratio | 264.26% | 242.12% | 250.36% | Thousands | SGD |
| Quick Ratio | 226.44% | 202.24% | 209.85% | Thousands | SGD |
| Interest Coverage | N/A | N/A | N/A | Thousands | SGD |
| Asset Turnover | 71.36% | 69.48% | N/A | Thousands | SGD |
| Debt-to-Equity | 128.35% | 151.27% | 161.53% | Thousands | SGD |
| Return on Equity | 12.36% | 10.79% | N/A | Thousands | SGD |
| Return on Assets | 5.16% | 4.21% | N/A | Thousands | SGD |
| Effective Tax Rate | 11.43% | 18.96% | 16.96% | Thousands | SGD |
| Dividend Payout Ratio | 67.38% | 64.96% | N/A | Thousands | SGD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Core dental business: $173,787, Other businesses: $6,887 | Primary healthcare: $167,765, Dental equipment and supplies distribution: $8,443, Medical laboratory: $6,515 | Primary healthcare: $160,895, Dental equipment and supplies distribution: $11,236, Medical laboratory: $9,083 |
| Revenue by Geographic Region | Singapore: $167,319, Malaysia: $13,355, China: - | Singapore: $171,438, Malaysia: $11,116, China: $169 | Singapore: $167,288, Malaysia: $13,139, China: $787 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue showed a slight decline from 2022 ($181,214) to 2023 ($182,723), followed by a further decrease in 2024 to $180,674. The gross margin decreased from 113.89% in 2022 to 111.67% in 2023, and slightly further to 111.31% in 2024, indicating a downward trend in profitability relative to revenue. The revenue breakdown indicates a shift towards the core dental business, which generated $173,787 in 2024, compared to $167,765 from primary healthcare in 2023. The geographic distribution shows a decrease in revenue from Singapore from $171,438 in 2023 to $167,319 in 2024, while revenue from Malaysia increased from $11,116 to $13,355, and revenue from China was eliminated in 2024. |
| Operating Efficiency | Operating margin data is not available for 2023 and 2024, but the operating expenses increased from -$103,612 in 2022 to -$108,853 in 2023, and further to -$105,886 in 2024, indicating a potential challenge in cost management. The net profit margin improved from 6.06% in 2023 to 7.23% in 2024, suggesting that despite rising operating expenses, the company managed to enhance profitability relative to revenue. |
| External & One-Off Impact | The effective tax rate decreased from 18.96% in 2023 to 11.43% in 2024, which positively impacted net profit, increasing from $11,073 in 2023 to $13,066 in 2024. There are no non-recurring items mentioned, but the elimination of revenue from China and the shifts in revenue from Singapore and Malaysia could indicate external market challenges affecting profitability. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets decreased to SGD 247,773,000 from SGD 258,588,000 in 2023, indicating a decline in asset base. However, total liabilities also decreased to SGD 139,266,000 from SGD 155,677,000, which reflects improved liability management. Shareholders' equity increased to SGD 108,507,000 from SGD 102,911,000, suggesting a strengthening equity position. The current ratio improved to 264.26%, indicating strong liquidity and a solid capital structure. | In 2023, total assets were SGD 258,588,000, down from SGD 267,412,000 in 2022, showing a trend of asset reduction. Total liabilities also decreased to SGD 155,677,000 from SGD 165,164,000, which is a positive sign of liability management. Shareholders' equity rose to SGD 102,911,000 from SGD 102,248,000, indicating a stable equity position. The current ratio was 242.12%, reflecting adequate liquidity and a healthy capital structure. |
| Profitability and earnings quality | In 2024, revenue decreased slightly to SGD 180,674,000 from SGD 182,723,000 in 2023, while net profit increased to SGD 13,066,000 from SGD 11,073,000, indicating improved profitability despite lower revenue. The net profit margin improved to 7.23% from 6.06%, suggesting better cost management. Return on equity (ROE) increased to 12.36% from 10.79%, indicating enhanced earnings quality and sustainability. | In 2023, the company reported revenue of SGD 182,723,000, a slight increase from SGD 181,214,000 in 2022. Net profit was SGD 11,073,000, up from the previous year, reflecting a positive trend in profitability. The net profit margin was 6.06%, indicating moderate profitability. ROE was 10.79%, suggesting a reasonable return on equity, although there was room for improvement in earnings quality. |
| Operational efficiency | In 2024, the operating expenses decreased to SGD 105,886,000 from SGD 108,853,000 in 2023, indicating improved cost management. The asset turnover ratio increased to 71.36% from 69.48%, suggesting better asset utilization. Net cash from operations rose significantly to SGD 40,098,000 from SGD 33,260,000, indicating strong operational efficiency and effective working capital management. | In 2023, operating expenses were SGD 108,853,000, up from SGD 103,612,000 in 2022, indicating challenges in cost management. The asset turnover ratio was 69.48%, showing moderate asset utilization. Net cash from operations was SGD 33,260,000, which was an improvement from SGD 39,746,000 in 2022, suggesting some operational efficiency but still indicating potential for further improvement. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved to 128.35% from 151.27% in 2023, indicating better leverage management. The current ratio of 264.26% suggests strong liquidity, while the effective tax rate decreased to 11.43% from 18.96%, which may reduce tax-related risks. Overall, the financial risk profile appears to be improving. | In 2023, the debt to equity ratio was 151.27%, indicating higher leverage and potential financial risk. The current ratio was 242.12%, which still indicated adequate liquidity. The effective tax rate was 18.96%, higher than in 2024, suggesting potential tax risks. Overall, the financial risk profile was more concerning compared to 2024. |
| Future financial performance projection | Based on 2024 data, the company is likely to continue focusing on cost management and operational efficiency, which should support profitability. The increase in net cash from operations suggests a sustainable cash flow position, which may allow for continued investment in growth initiatives. The dividend policy appears to be conservative, with dividends increasing to SGD 8,804,000, indicating a focus on retaining earnings for future growth. | In 2023, the company showed signs of stabilizing its financial performance, with a focus on managing costs and improving profitability. The net cash from operations was positive, but the increase in dividends to SGD 7,193,000 indicated a cautious approach to cash distribution. Future projections would depend on maintaining revenue growth and managing operational costs effectively. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | The company's primary business model is based on the rendering of dental services and the sale of dental goods. Revenue is generated primarily through the provision of dental services, which accounted for approximately 93.5% of total revenue in FY2024, and the sale of dental goods, which contributed around 4.1%. The core dental business includes operating dental clinics and distributing dental supplies and equipment, targeting individuals and private dental clinics. Additionally, the company earns profit guarantee income and rental income, further diversifying its revenue streams. | The company primarily operates through the rendering of services and the sale of goods. Revenue is recognized at a point in time when the performance obligation is satisfied, typically upon delivery of goods or completion of services. The main revenue streams include rendering of services (S$171,016,000), sale of goods (S$8,277,000), profit guarantee income (S$2,388,000), and rental income (S$503,000). The target markets include individuals for primary healthcare services, private dental clinics for dental equipment and supplies, and vaccination centers for medical laboratory services. |
| Market Position | Q & M Dental Group is positioned as the largest private dental network in Singapore, operating 106 clinics. The company maintains a strong market presence with a focus on high-growth regions, particularly in Malaysia, where it has strategically consolidated its operations. The core dental business revenue grew marginally to S$173.8 million in FY2024, driven by higher patient volumes, particularly in Malaysia. The company is recognized as a market leader in the dental healthcare sector in Southeast Asia, with ongoing efforts to expand its footprint and enhance service offerings. | The company is positioned as a leading player in the dental healthcare sector, operating the largest network of private dental outlets in Singapore with 106 clinics and 44 clinics in Malaysia. It serves approximately 42,000 patient visits per month. The company aims to be the leading dental healthcare group in the region, leveraging its extensive network and commitment to ethical practices. Specific market share data is not provided, but the company is recognized as a market leader in its key markets. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The company faces market risks related to competition and demand volatility, particularly in the dental healthcare sector. The cessation of the medical laboratory business due to the expiry of its clinical laboratory service license may impact market positioning and revenue streams. | The company faces market risks due to challenging macroeconomic conditions, including geopolitical instability, high interest rates, and inflation, which could affect demand for its services and products. Management has reviewed potential impacts and downside scenarios but identified no material uncertainties regarding operational continuity. |
| Operational Risks | Operational challenges arose from the decision to cease the medical laboratory business, which could affect service delivery and operational efficiency. The company is actively optimizing assets and streamlining operations to mitigate these risks. | Operational risks include challenges in managing the supply chain and maintaining operational efficiency, particularly as the company streamlines operations and ceases the operation of underperforming clinics. The company regularly reviews its business activities to identify and mitigate significant operational risks. |
| Financial Risks | The company is exposed to financial risks including credit risk, liquidity risk, and interest rate risk. Management has established procedures to manage these risks, including the use of natural hedges and derivatives for hedging purposes. | Financial risks include exposure to foreign currency and interest rate fluctuations, with sensitivity analyses indicating that the impact on post-tax profit is not significant. The company also faces credit risk from concentrations in financial assets and liquidity risk related to meeting financial obligations, which is managed through regular monitoring and maintaining undrawn borrowing facilities. |
| Compliance Risks | The company is committed to complying with regulatory requirements and has established internal protocols to ensure adherence to laws and regulations. The Board oversees compliance and risk management strategies to safeguard the company's interests. | The company adheres to regulatory compliance and legal requirements, with internal protocols in place to ensure alignment with relevant authorities. The Board oversees compliance and risk management strategies to safeguard the interests of the company and its stakeholders. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Mr Tan Teck Koon | Independent Non-Executive Chairman | S$60,000 |
| Mr Lim Yeow Hua | Independent Non-Executive Director | S$42,740 |
| Prof Chew Chong Yin | Independent Non-Executive Director | S$26,164 |
| Dr Ng Chin Siau | Non-Independent Executive Director/Group Chief Executive Officer | S$788,090 |
| Dr Ang Ee Peng Raymond | Alternate Director to Dr Ng Chin Siau | S$361,683 |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Company regularly reviews and improves its business and operational activities to identify areas of significant business risks and takes appropriate measures to control and mitigate these risks. The Group has put in place documentation on its risk profile summarizing the material risks faced and the countermeasures in place, which is reviewed by the Board annually. | The Group has put in place documentation on its risk profile which summarises the material risks faced by the Group and the countermeasures in place to manage or mitigate those risks for the review by the Board annually. Risk assessment and evaluation has become an essential part of the business planning and monitoring process. |
| Control activities | The Company maintains a sound system of risk management and internal controls to safeguard the interests of the Company and its shareholders. The Audit Committee (AC) is responsible for developing and maintaining effective systems of internal controls, ensuring compliance with applicable laws and regulations, and reviewing significant policies governing the operations of the Company. | The Company maintains robust internal controls to safeguard shareholders' investment and the Company's business and assets. The internal audit function is outsourced to CLA Global, which assesses if adequate systems of internal controls are in place, conducts regular in-depth audits of high-risk areas, and identifies and recommends improvements to internal control procedures. |
| Monitoring mechanisms | The AC meets at least half-yearly to review the audit plan, internal controls, and financial statements. The internal audit function is outsourced to CLA Global, which reports directly to the AC. The AC also meets with internal and external auditors without management present at least once a year to ascertain any material weaknesses or control deficiencies. | The Audit Committee (AC) reviews the internal audit's plan, evaluates the internal control systems, and ensures coordination between external auditors and Management. The AC meets at least half-yearly to discuss audit plans, results, and any suspected fraud or irregularities. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | The Board, with the concurrence of the AC, is of the opinion that the Group's risk management and internal control systems were adequate and effective as at 31 December 2024 to address the risks that the Group considers relevant and material to its operations. | The Board, with the concurrence of the audit committee, is of the opinion that the Company's internal controls (including financial, operational, compliance, and information technology controls) and risk management systems were adequate and effective as at 31 December 2023 to address the risks that the Company considers relevant and material to its operations. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | In FY2024, the Group acquired the business and assets of Veritas Dental Pte. Ltd. for a cash consideration of $800,000, enhancing its clinic network in Singapore. Additionally, the Group is exploring merger and acquisition opportunities in Singapore, Malaysia, and China as appropriate opportunities arise. | In 2023, Q & M entered into a joint-venture agreement with EM2AI Professional Holdco Pte. Ltd., which involved an investment of S$1.6 million into the Group's subsidiary EM2AI Pte. Ltd. Additionally, an interest-free loan of S$3.7 million was provided to EM2AI for working capital purposes. This joint venture allows Q & M to strengthen its financial position while minimizing capital investment during EM2AI's growth stage. |
| New technologies | The Group is advancing its AI initiatives through EM2AI, which includes deploying AI-powered dental charting using OPG and digital intra-oral cameras across all clinics by the end of FY2025. A strategic partnership was established with a major dental solutions provider in SEA to integrate EM2AI's dental AI solutions into their platform, expanding its reach to over 1,100 clinics across multiple countries. | Q & M is focusing on advancing its capabilities in Artificial Intelligence (AI) and has made significant investments in this area. The company has developed the AI Guided Clinical Decision Support System (AI-GCDSS) and the cloud-based Integrated Dental Management System (EM2Clinic). These technologies aim to enhance patient care by providing ethical, efficient, and effective treatment solutions. The company is also rolling out a Guided Clinical Decision Support System in selected outlets for testing. |
| Organisational Restructuring | The Group is focusing on workforce development by training dentists to incorporate AI-Clinical Decision Support Systems (AI-CDSS) into their practice, enhancing diagnostic precision. Additionally, the Q & M College of Dentistry received EduTrust Provisional Certification, allowing it to enroll international students and diversify revenue streams. | In 2023, Q & M restructured its management by organizing area management teams that include dentists, nurses, operations, and finance personnel to improve productivity and operational efficiencies across its dental clinics. Area Managers have been empowered to make improvements to work processes, which is part of the Group's strategy to enhance overall cost and operational efficiencies. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The company faces significant economic challenges, including the need to manage financial risks such as credit risk, liquidity risk, and market risk, which encompasses interest rate, currency, and price risk exposures. The management has established procedures to mitigate these risks, but uncertainties in future market conditions could impact revenue and profitability. Additionally, the assessment of impairment of goodwill and the estimation of income tax amounts involve significant judgment and could lead to material adjustments in financial statements based on actual outcomes differing from estimates. | The conditions remain challenging with geopolitical instability affecting domestic and global growth in the current high interest environment. There has been a widespread increase in interest rates and a significant rise in inflation, impacting the cost of goods and services for customers and suppliers. Management has considered the uncertain macroeconomic and geopolitical environment that could affect business performance. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The company is navigating competitive pressures from both established industry players and new entrants in the dental healthcare market. The strategic expansion efforts, including the acquisition of Veritas Dental and the integration of AI-driven solutions, are aimed at strengthening its market position. However, the competitive landscape remains dynamic, with technological disruptions and the need for continuous innovation posing challenges to maintaining market leadership. | N/A |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | In FY2024, Q & M Dental Group focused on advancing technology through significant investments in R&D, particularly in AI-driven solutions. The company allocated funds to develop EM2AI's AI-powered diagnostic tools, which received regulatory approvals in multiple Southeast Asian countries, enabling access to a market of over 600 million people. The integration of AI in dental charting and patient management systems was a key initiative, enhancing operational efficiency and patient care. | In 2023, Q & M Dental Group's Research and Development (R&D) division focused on advancing technology in dental healthcare, particularly through the development of AI-driven solutions. The Group has made significant investments in its AI Guided Clinical Decision Support System (AI-GCDSS) and the cloud-based Integrated Dental Management System (EM2Clinic). The total development costs for R&D increased to S$4,363,000, reflecting a commitment to enhancing diagnostic capabilities and treatment planning through technology. The Group aims to commercialize its pipeline of PCR tests for infectious diseases and cancer, driving innovation and new product development to meet evolving healthcare needs. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | Q & M Dental Group launched several innovative products in FY2024, including the EM2Clinic, a cloud-based Integrated Dental Management System, and the Q & M Patient App. These products feature advanced functionalities such as secure storage of dental records, AI detection modules, and integration with intra-oral cameras, significantly improving patient experience and operational processes. The company aims to differentiate itself in the market by leveraging these technologies to enhance patient-centric care. | In 2023, Q & M Dental Group launched the Q & M Dental mobile app in Malaysia, which facilitates real-time appointment bookings, allowing patients to select their preferred time, location, and dentist. This app has become a vital tool for patients, enhancing their overall experience. Additionally, the Group has rolled out AI detection modules across its clinics, improving diagnostic accuracy and treatment planning. The introduction of the AI-driven Guided Clinical Decision Support System (GCDSS) is currently in trial phases, aiming to enhance the speed and accuracy of dental diagnoses and treatment plans. |
